Ionis製藥 IONS 深 滬
已收盤 12-24 16:00:00 美东时间
80.65
+0.320
+0.40%
華盛通- 最 高81.02
- 今 開80.33
- 成交量 48.02万股
- 最 低 80.33
- 昨 收 80.33
- 總市值 130.65亿
- 52周最高 83.61
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 23.95
- 委 比 99.51%
- 總股本 1.62亿
- 歷史最高 86.582
- 量 比 0.22
- 振 幅 0.86%
- 歷史最低 6.25
- 每 手 1
- 風險率 17.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks
Cathie Wood made a few trades across ARKETFson Friday, December 19,...
12-22 11:37
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $85 to $100.
12-16 04:45
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.
12-03 23:09
Ionis gets FDA breakthrough therapy status for zilganersen
Ionis Pharmaceuticals (IONS) has received breakthrough therapy designation from the U.S. FDA for its drug zilganersen, aimed at treating Alexander disease, a rare and often deadly neurological disorde...
12-02 22:03
2025年度十大医药技术研报，解码产业创新与全球化新机遇
（来源：E药资本界） 2025年，中国医药健康产业正式迈入“创新深化+全球突围”双轮驱动的关键阶段。以小核酸、PROTAC、CGT为代表的新兴疗法从临...
12-02 19:28
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.
11-25 23:14
Arrowhead rises as FDA approves lead drug for rare disorder
Shares of Arrowhead Pharmaceuticals (ARWR) gained on Tuesday after the U.S. FDA approved its lead asset Redemplo (plozasiran) for adults with a rare genetic disorder called familial chylomicronemia sy...
11-19 01:50
